Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer immunology research

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-14-0207PMID 25736262PMCID PMC4351797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

  2014cited by this paper
• Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

  2013influential reference
• Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

  2013cited by this paper
• Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab.

  2013cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

  2013cited by this paper
• Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma

  2012cited by this paper
• Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

  2012cited by this paper
• Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.

  2012cited by this paper
• Overall survival and PD‐L1 expression in metastasized malignant melanoma

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

  2011influential reference
• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

  2011cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Ipilimumab: controversies in its development, utility and autoimmune adverse events

  2009cited by this paper
• Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

  2006cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper

• Melanoma: Pathogenesis and Targeted Therapy

  2026influential citation
• Comprehensive Genomic Profiling of Acral Melanoma: Insights From the AACR Project GENIE Database.

  2026cites this paper
• Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations

  2026cites this paper
• ZNF180 modulates tumor intrinsic immunotherapy resistance in melanoma through driving plasticity

  2025cites this paper
• Predicting response and survival of lung adenocarcinoma under anti-programmed death-1 therapy using biological deep learning

  2025cites this paper
• Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic.

  2025cites this paper
• Combination Immunotherapy for Mucosal Melanoma: Molecular Mechanism, Research Status, and Future Directions

  2025cites this paper
• Notch signaling and cancer: Insights into chemoresistance, immune evasion, and immunotherapy.

  2025cites this paper
• NRASQ61K/R/L Mutant Allele Frequency in Melanoma and its Correlation With Clinicopathological Characteristics

  2025cites this paper
• Sustained Immunotherapy Response in Metastatic Brain Melanoma Through 2 Pregnancies

  2025cites this paper
• Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis

  2025cites this paper
• Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy.

  2025cites this paper
• Atomic-level mechanisms of abnormal activation in NRAS oncogenes from two-dimensional free energy landscapes.

  2025cites this paper
• Novel methyl-substituted pyrrole hydrazones as selective melanoma agents

  2025cites this paper
• Immune checkpoint inhibitors in metastatic melanoma therapy (Review)

  2024cites this paper
• Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations

  2024cites this paper
• Molecular Susceptibility and Treatment Challenges in Melanoma

  2024cites this paper
• Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients

  2024cites this paper
• Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients

  2024cites this paper
• Isomer-sourced structure iteration methods for in silico development of inhibitors: Inducing GTP-bound NRAS-Q61 oncogenic mutations to an “off-like” state

  2024cites this paper
• Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis

  2024cites this paper
• A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

  2024cites this paper
• Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report

  2024cites this paper
• Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

  2023cites this paper
• Clinical immunotherapeutic significance of RAS gene mutations in melanoma

  2023cites this paper
• Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study

  2023cites this paper
• Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective

  2023cites this paper
• Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

  2023cites this paper
• Pathology and Molecular Biology of Melanoma

  2023cites this paper
• A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations

  2023cites this paper
• Pediatric Primary Intracranial Malignant Melanoma: Case Report and Literature Review

  2023cites this paper
• Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.

  2023cites this paper
• Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations

  2023cites this paper
• Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.

  2023cites this paper
• MicroRNA-708 emerges as a potential candidate to target undruggable NRAS

  2023cites this paper
• Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.

  2023cites this paper
• Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.

  2023cites this paper
• Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis

  2023cites this paper
• Oncogenic drivers dictate immune control of acute myeloid leukemia

  2023cites this paper
• Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy

  2023cites this paper
• Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma

  2022cites this paper
• Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives

  2022cites this paper
• Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients

  2022cites this paper
• MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.

  2022cites this paper
• The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

  2022cites this paper
• RAS pathway regulation in melanoma

  2022cites this paper
• Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

  2022cites this paper
• Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

  2022cites this paper
• Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma

  2022cites this paper
• The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma

  2022cites this paper
• A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.

  2022cites this paper
• NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma

  2022cites this paper
• Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease

  2022cites this paper
• Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

  2022cites this paper
• Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma

  2021influential citation
• NRAS mutant melanoma: Towards better therapies.

  2021cites this paper
• Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma

  2021cites this paper
• Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies

  2021cites this paper
• Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma

  2021cites this paper
• Advanced Melanoma: Resistance Mechanisms to Current Therapies.

  2021cites this paper
• MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSE

  2021cites this paper
• No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study

  2021cites this paper
• Effect of atmospheric plasmas on drug resistant melanoma: the challenges of translating in vitro outcomes into animal models

  2021cites this paper
• Primary pulmonary choriocarcinoma in male: report a case with genetic testing and review of the literature

  2021cites this paper
• Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

  2021cites this paper
• Is cancer biology different in older patients?

  2021cites this paper
• Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score

  2021cites this paper
• Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

  2021cites this paper
• Personalised medical management of patients with melanoma (part 2)

  2021cites this paper
• OTT_A_278095 3709..3719

  2021influential citation
• Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

  2021cites this paper
• TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

  2021cites this paper
• Novel insights into the pathogenesis and treatment of NRAS mutant melanoma

  2021cites this paper
• BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.

  2021cites this paper
• Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

  2021cites this paper
• Primary tumor characteristics and next‐generation sequencing mutations as biomarkers for melanoma immunotherapy response

  2020cites this paper
• Precision Medicine in the Treatment of Melanoma.

  2020cites this paper
• SnapshotDx Quiz: January 2020.

  2020cites this paper
• Predictive biomarkers of response to immune checkpoint inhibitors in melanoma

  2020cites this paper
• Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

  2020cites this paper
• Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

  2020cites this paper
• Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma

  2020cites this paper
• Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma

  2020cites this paper
• Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives

  2020cites this paper
• Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data

  2020cites this paper
• Subversion of Ras Small GTPases in Cutaneous Melanoma Aggressiveness

  2020cites this paper
• Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

  2020cites this paper
• Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft

  2020cites this paper
• Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.

  2020cites this paper
• Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.

  2020influential citation
• NRAS Q61R-mutant mucosal melanoma with cardiac metastasis - a diagnostic challenge

  2020cites this paper
• Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

  2019cites this paper
• Introduction to Melanoma Immunology

  2019cites this paper
• Circulating biomarkers predictive of tumor response to cancer immunotherapy

  2019cites this paper
• Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

  2019cites this paper
• Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.

  2019cites this paper
• Neuroblastoma rat sarcoma mutated melanoma: That’s what we got so far

  2019cites this paper
• Role of tumor gene mutations in treatment response to immune checkpoint blockades

  2019cites this paper
• Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

  2019cites this paper
• Integrated molecular and clinical staging defines the spectrum of metastatic cancer

  2019cites this paper